Literature DB >> 7019531

The Albright syndrome associated with acromegaly: report of a case and review of the literature.

A Lipson, T H Hsu.   

Abstract

The association of the Albright syndrome (polyostotic fibrous dysplasia of bone, hyperpigmented skin macules, and endocrine disorders) with acromegaly has been infrequently substantiated. The case of an 18-year-old girl with the classic Albright syndrome and acromegaly is described. The patient had a history of coarsening of acral and facial features, an insulin-resistant form of diabetes mellitus and elevated fasting growth hormone values. Neuro-endocrine studies demonstrated failure of growth hormone to suppress to less than 5 ng/ml during an oral glucose tolerance test, and the abnormal release of growth hormone upon injection of thyrotropin-releasing hormone. Although L-dopa failed to decrease growth hormone levels, bromocriptine produced a modest decline in growth hormone within two hours of ingestion. The patient had also experienced secondary amenorrhea with sub-normal follicle-stimulating-hormone (FSH) and luteinizing hormone (LH) levels, both of which demonstrated a prolonged sluggish response to an injection of gonadotropin-releasing hormone (GnRH); this response suggested hypogonadotropic hypogonadism, possibly on the basis of a tumor involving both pituitary and hypothalamus. Sellar polytomography demonstrated an enlarged sella with dorsal erosion and an asymmetric floor. Computerized tomography of the brain visualized a suprasellar mass extending into the hypothalamus. These findings suggest a hypersecretion of hypothalamic releasing factors, pituitary hormones, or both as an etiology for the endocrinopathy in this patient, and lend support to the theory that the endocrinopathies associated with the Albright syndrome result from over-production of hypothalamic-releasing hormones or autonomous secretion of pituitary hormones from an adenoma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7019531

Source DB:  PubMed          Journal:  Johns Hopkins Med J        ISSN: 0021-7263


  9 in total

1.  Octreotide therapy of growth hormone excess in the McCune-Albright syndrome.

Authors:  S I Sherman; P W Ladenson
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

2.  Acromegaly, multinodular goiter and silent polyostotic fibrous dysplasia. A variant of the McCune-Albright syndrome.

Authors:  R Abs; A Beckers; F L Van de Vyver; A De Schepper; A Stevenaert; G Hennen
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

Review 3.  A case of pituitary adenoma associated with McCune-Albright syndrome.

Authors:  S Sakaki; S Yokoyama; K Mamitsuka; M Nakayama; M Goto; J Kuratsu
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

Review 4.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

5.  Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis.

Authors:  K Kovacs; E Horvath; M O Thorner; A D Rogol
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

Review 6.  Acromegaly and McCune-Albright syndrome.

Authors:  Sylvie Salenave; Alison M Boyce; Michael T Collins; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

7.  Fibrous dysplasia of the skull with acromegaly and sarcomatous transformation. Two cases with a review of the literature.

Authors:  A Mortensen; M Bojsen-Møller; P Rasmussen
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

8.  Acromegaly and hyperprolactinemia in a patient with polyostotic fibrous dysplasia: dynamic endocrine studies and treatment with the somatostatin analogue octreotide.

Authors:  M B Garcia; H P Koppeschaar; C J Lips; J H Thijssen; E P Krenning
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

9.  Unusual manifestations of craniofacial fibrous dysplasia: clinical, endocrinological and computed tomographic features.

Authors:  B D Daly; C C Chow; C S Cockram
Journal:  Postgrad Med J       Date:  1994-01       Impact factor: 2.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.